Zacks Investment Research Lowers Osmotica Pharmaceuticals (NASDAQ:OSMT) to Sell

Zacks Investment Research cut shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a sell rating in a research report released on Friday morning, reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Several other brokerages also recently weighed in on OSMT. Barclays began coverage on Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They issued an overweight rating and a $11.00 price target for the company. Wells Fargo & Co set a $14.00 price target on Osmotica Pharmaceuticals and gave the company a buy rating in a report on Thursday, March 28th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $14.00.

Shares of Osmotica Pharmaceuticals stock opened at $3.29 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41. Osmotica Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $9.90. The company has a market cap of $169.50 million and a P/E ratio of -6.45.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.08). The company had revenue of $57.13 million during the quarter, compared to analysts’ expectations of $53.58 million. On average, analysts forecast that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. JW Asset Management LLC purchased a new stake in shares of Osmotica Pharmaceuticals in the fourth quarter worth about $1,744,000. BlackRock Inc. acquired a new position in Osmotica Pharmaceuticals in the 4th quarter worth about $3,682,000. Northern Trust Corp acquired a new position in Osmotica Pharmaceuticals in the 4th quarter worth about $615,000. Geode Capital Management LLC acquired a new position in Osmotica Pharmaceuticals in the 4th quarter worth about $668,000. Finally, American International Group Inc. acquired a new position in Osmotica Pharmaceuticals in the 4th quarter worth about $50,000. Institutional investors own 11.64% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with's FREE daily email newsletter.